Novo Nordisk's new long-acting insulin, Tresiba, has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage ...
The Tresiba label was updated to reflect safety outcomes from the DEVOTE trial. Novo Nordisk announced that the Food and Drug Administration (FDA) has approved an update to the prescribing information ...
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...
Bagsværd, 29 November 2016 - Today, Novo Nordisk announced the headline results from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the ...
Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...
Bagsværd, Denmark, 23 February 2016 - Novo Nordisk today announced the headline results from SWITCH 1, the second of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback